Investor Presentaiton

Strong business momentum Diversified portfolio growth Efficient compounding engine Sustainable long-term growth Layering of future royalty acquisitions has compounding effect Illustrative projected annual Adjusted Cash Receipts (1,2) ("top-line") Assumes $2.0-2.5bn annual deployment through 2030 2022-2024 royalty acquisitions 2021 2022e 2023e 2025-2027 royalty acquisitions 2024e 2025e 2026e 2028-2030 royalty acquisitions 2027e 2028e 2029e 2030e >$2.5bn (+/-$500m) $0.4bn (+/- $100m) $1.0bn (+/- $200m) $1.2bn (+/- $200m) $2.0-2.5bn of average annual royalty acquisitions estimated to add >$2.5bn to Adjusted Cash Receipts in 2030 ROYALTY PHARMA 1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook. 2. Illustrative analysis calculated using representative cash receipts based on blended average of actual and projected returns for approved and development-stage transactions over the last five years under a range of scenarios. Assumes $2.0-$2.5bn of capital deployed on average per year through 2030. 101

View entire presentation